Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.65 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299163 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL18588287 | 0.93 | CASP2 (0.55) | CASP2NAAAFAAHEPHX2MEN1 | |
| SCHEMBL19477862 | 0.93 | CASP2 (0.58) | CASP2NAAAFAAHMEN1KMT2A | |
| SCHEMBL27142733 | 0.91 | CASP2 (0.61) | CASP2NAAAFAAHDNM1LPAR1 | |
| SCHEMBL280231 | 0.91 | CASP2 (0.60) | CASP2NAAAFAAHDNM1 | |
| SCHEMBL24759152 | 0.90 | FAAH (0.59) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL7650140 | 0.89 | FAAH (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL13811075 | 0.89 | FAAH (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL7646590 | 0.89 | FAAH (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL7647954 | 0.89 | FAAH (0.62) | CASP2NAAAFAAHEPHX2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CASP2 4430/4885NAAA 4405/4885FAAH 2901/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CASP2 4432/4885NAAA 4848/4885FAAH 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.